ClinicalTrials.gg
RecruitingNCT06936670IMSTUpdated Jun 13, 2025

Effects of High-Resistance Inspiratory Muscle Strength Training on Cardiorenal and Vascular Function in Youth and Young Adults With Type 2 Diabetes

An interventional study of Inspiratory Muscle Strength Training (IMST) and Sham Training in Diabetes Mellitus Type 2, sponsored by Seattle Children's Hospital. Recruiting at 2 sites in United States. Open to participants aged 14 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Seattle Children's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
14 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
1,480th of 2,961
90 · median 90
Started
2025
with 138 others
No phase
1,242 of 3,308
200 open now
Primary completion
2026-02
later than 78 of 477 live
Registered
3,072nd of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,480th largest by planned enrollment of the 2,961 interventional ones that give a count, is one of 139 that started in 2025, is one of 1,242 with no phase, reaches primary completion later than 78 of the 477 other live ones, and was the 3,072nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 14 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

High-resistance, short-duration inspiratory muscle strength training (IMST) is a novel lifestyle intervention involving 30 inhalations against a resistive load which requires only \~5 min/day and is thus ideal for youth with T2D (Y-T2D). Investigators seek to 1: assess changes in casual and 24-hr SBP, endothelial function, and arterial stiffness after 3 months of IMST vs. sham training in Y-T2D, 2: Define changes in eGFR andalbuminuria after 3 months of IMST vs. sham in Y-T2D, 3: Interrogate mechanisms of IMST by translational assessments of NO bioavailability, endothelial NO synthase (eNOS) activation, and ROS/oxidative stress, and determine the role of circulating factors.

03

Conditions studied

  • Diabetes Mellitus Type 2

Keywords

  • Type 2 Diabetes
  • Inspiratory Strength Training
  • Blood Pressure
  • Kidney Health
  • Cardiovascular Function
  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
14 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Aged 14-40, have had T2D for a least one year, less than 12%.

-

Exclusion Criteria: Have had type II diabetes for more than 18 years, estimated (eGFR) less than 60 ml/min/1.73m2 or Albumin-to-creatinine ratio (ACR) greater than 2200mg/g, blood pressure greater than 160/100 mm Hg.

-

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    IMST

    Using the POWERBreathe pressure threshold training device, participants will perform 30 inspiratory maneuvers (5 sets of 6, 1 min rest) 6 days/week for 3 months. This is an over the counter product that will be used according to its instructions. The IMST group will train at 75% maximal inspiratory pressure.

    Device: Inspiratory Muscle Strength Training (IMST)

  • Sham comparator
    Sham/Placebo

    Using the POWERBreathe pressure threshold training device, participants will perform 30 inspiratory maneuvers (5 sets of 6, 1 min rest) 6 days/week for 3 months. This is an over the counter product that will be used according to its instructions. The Sham group will train at 15% maximal inspiratory pressure.

    Device: Sham Training

Interventions

  • DeviceInspiratory Muscle Strength Training (IMST)

    A novel form of physical training that uses the diaphragm and accessory respiratory muscles to repeatedly inhale against resistance using a handheld device, generating large negative intrathoracic pressures. The device can be set to different levels of resistance, meaning the intervention and sham groups will undergo the same training, but at 75% and 15% of their maximal inspiratory pressure respectively.

  • DeviceSham Training

    The same training regiment but at much lower resistance, offering little to strength training impact.

06

What researchers measure

Primary outcomes

  1. Systolic Blood Pressure

    Measures of casual clinic and 24-hour ambulatory blood pressure monitoring

    Time frame: 3 months

Secondary outcomes

  1. Endothelial function

    Measured by brachial artery flow-mediated dilation and endothelial cell collection and analysis.

    Time frame: 3 months

  2. Arterial stiffness

    Measured by carotid-femoral pulse-wave velocity and carotid-radial pulse-wave analysis using a SphygmoCor.

    Time frame: 3 months

  3. Kidney Function

    Measured by estimated glomerular filtration rate and albuminuria assessments

    Time frame: 3 months

  4. Body Composition

    Measured by BIS (Bioimpedance spectroscopy)

    Time frame: 3 months

07

Study locations

1 of 2 sites recruiting
  • Seattle Children's Hospital
    Seattle, Washington 98102, United States
    Recruiting
    • Kalie Tommerdahl · Contactktomme@uw.edu · 206-616-9015
    • Kalie Tommerdahl, MD · Principal investigator
  • University of Washington Medicine Diabetes Institute
    Seattle, Washington 98109, United States
    Not yet recruiting
    • Kalie Tommerdahl, MD · Contactktomme@uw.edu · 206) 616-9015
    • Kalie Tommerdahl, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2026, 9 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 9 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 20, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2026
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06936670
Responsible party
Kalie Tommerdahl (Associate Professor of Pediatrics in the Division of Endocrinology and Diabetes at Seattle Children's Hospital and the University of Washington School of Medicine, Seattle Children's Hospital) — Principal investigator
First posted
Apr 20, 2025
Start date
Apr 30, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Jun 13, 2025

Study contacts

Kalie Tommerdahl, MD
Contact
ktomme@uw.edu
(206) 616-9015

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion